Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dibenzepin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 4/20 | 1.00 |
| ▸ | HTR6 | P50406 | 4/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | HTR7 | P34969 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HEXA | P06865 | 1/20 | 0.55 |
| ▸ | HEXB | P07686 | 1/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dibenzepin SCHEMBL49286 | 1.00 | HRH1 (1.00) | HRH1DRD2HTR6SLC6A4HTR1A | |
| Dibenzepin SCHEMBL668219 | 0.98 | HRH1 (0.97) | HRH1DRD2HTR6SLC6A4HTR1A | |
| Dibenzepin SCHEMBL29375228 | 0.98 | HRH1 (0.97) | HRH1DRD2HTR6SLC6A4HTR1A | |
| Dibenzepin SCHEMBL14973430 | 0.97 | HRH1 (0.94) | HRH1DRD2HTR6SLC6A4HTR1A | |
| Dimetacrine SCHEMBL28221926 | 0.84 | HRH1 (0.71) | HRH1DRD2HTR6SLC6A4HTR1A | |
| SCHEMBL11746213 | 0.84 | HRH1 (0.72) | HRH1DRD2HTR6SLC6A4HTR1A | |
| SCHEMBL29492639 | 0.83 | HRH1 (0.69) | HRH1DRD2HTR6SLC6A4HTR1A | |
| Dibenzepin SCHEMBL28086113 | 0.82 | HRH1 (0.68) | HRH1DRD2HTR6SLC6A4HTR1A | |
| SCHEMBL30839875 | 0.81 | HEXA (0.72) | HRH1DRD2HTR6SLC6A4HTR1A | |
| SCHEMBL13590076 | 0.81 | HEXA (0.72) | HRH1DRD2HTR6SLC6A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3946296-B9 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2024-12-25 | — | — | EP | claimed |
| EP-4479032-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | Sage Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | claimed |
| EP-3706762-B1 | N4-HYDROXYCYTIDINE DERIVATIVE AND ANTI-VIRAL USES RELATED THERETO | UNIV EMORY (US) | 2024-10-16 | — | — | EP | claimed |
| US-20240307386-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. | 2024-09-19 | — | — | US | claimed |
| EP-3946296-B1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2024-05-01 | — | — | EP | claimed |
| US-20230330111-A1 | ACTIVE AGENT COMBINATION FOR TREATMENT OF CANCER | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2023-10-19 | — | — | US | claimed |
| WO-2023158668-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | claimed |
| WO-2023159035-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | claimed |
| EP-4203944-A1 | ACTIVE AGENT COMBINATION FOR TREATMENT OF CANCER | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH (DE) | 2023-07-05 | — | — | EP | claimed |
| WO-2023282544-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT | 국립암센터 | 2023-01-12 | — | — | WO | claimed |
| WO-2022043490-A1 | ACTIVE AGENT COMBINATION FOR TREATMENT OF CANCER | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2022-03-03 | — | — | WO | claimed |
| US-12636509-B1 | Pharmacological wearable cardioverter defibrillator (WCD) | Rottenberg, Eric Marc (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260053748-A1 | NOVEL METHODS | INTRA CELLULAR THERAPIES INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260041667-A1 | PRESCRIPTION DIGITAL THERAPEUTICS | BECKLEY PSYTECH LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-20260034339-A1 | SUBCUTANEOUS BIODEGRADABLE RESERVOIR DEVICE | RES TRIANGLE INST (US) | 2026-02-05 | — | — | US | disclosed |
| EP-3970719-A1 | PDE1 INHIBITOR FOR USE IN A METHOD OF TREATMENT OR PROPHYLAXIS OF INFLAMMATION AND/OR AN INFLAMMATORY DISEASE OR DISORDER | Intra-Cellular Therapies, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20220073589-A1 | GPR156 Variants And Uses Thereof | REGENERON PHARMACEUTICALS, INC. | 2022-03-10 | — | — | US | disclosed |
| WO-2022043490-A1 | ACTIVE AGENT COMBINATION FOR TREATMENT OF CANCER | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2022-03-03 | — | — | WO | disclosed |
| EP-3949973-A2 | COMPOSITIONS AND METHODS FOR TREATING DEPRESSION | Gentelon, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3941583-A1 | COMPOSITION COMPRISING A BENZOATE SALT OF 5-METHOXY-N,N-DIMETHYLTRYPTAMINE | Beckley Psytech Limited (GB) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034339-A1 | SUBCUTANEOUS BIODEGRADABLE RESERVOIR DEVICE | CUTA, CD209, SLC19A1 | HRH1 2996/4885SLC6A2 928/4885DRD2 1358/4885 |
| US-20230330111-A1 | ACTIVE AGENT COMBINATION FOR TREATMENT OF CANCER | GLS2, AGK, GLS | HRH1 2138/4885SLC6A2 4016/4885DRD2 4706/4885 |
| US-20260053748-A1 | NOVEL METHODS | HTR1D, HTR2C, HTR1A | HRH1 71/4885SLC6A2 29/4885DRD2 18/4885 |
| US-20240307386-A1 | NOVEL METHODS | OPRL1, HTR2A, OPRM1 | HRH1 701/4885SLC6A2 174/4885DRD2 58/4885 |
| US-12636509-B1 | Pharmacological wearable cardioverter defibrillator (WCD) | WFS1, ADRA1D, GSDMD | HRH1 98/4885SLC6A2 1051/4885DRD2 25/4885 |
| US-20260041667-A1 | PRESCRIPTION DIGITAL THERAPEUTICS | HTR5A, PNMT, NPY5R | HRH1 1667/4885SLC6A2 9/4885DRD2 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.